Don't forget our competitors in the rnai field, Dicerna, Regulus, Artubus, Alnylam, are years ahead of us, having been through clinical trials, but with mixed results.
NVA Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter
ASX Market Open: Australian stocks rise on US market strength, as inflation data points to a Fed cut in September